Background
Methods
Study design
Patient recruitment and treatment
Angiographic analysis
CMR
Pre-discharge CMR
Follow-up CMR
CMR analysis
Clinical outcomes and follow-up
Statistical analysis
Results
Baseline characteristics
Variable | CvLPRIT cohort (n = 296) | Immediate CR (n = 63) | Staged CR (n = 30) |
p
|
---|---|---|---|---|
Age (y) | 64.9 ± 11.6 | 63.0 ± 11.6 | 65.0 ± 10.3 | 0.42 |
Male sex (%) | 240/296 (81.1) | 55 (87.3) | 28 (93.3) | 0.38 |
BMI (kg/m2) | 27.3 (24.4–30.2) | 27.7 ± 4.5 | 27.6 ± 4.1 | 0.95 |
Heart rate (beats per minute) | 74.4 ± 17.6 | 71.9 ± 16.4 | 73.5 ± 18.0 | 0.68 |
Systolic BP (mmHg) | 137.6 ± 27.1 | 132.6 ± 26.8 | 140.0 ± 27.7 | 0.23 |
Anterior infarct (%) | 106 (35.6) | 21 (33.3) | 11 (36.7) | 0.75 |
eGFR (ml/min/1.73) | 95.74 ± 34.7 | 96.1 ± 30.2 | 101.5 ± 41.0 | 0.49 |
Hypertension (%) | 105/287 (36.6) | 24 (38.1) | 10 (33.3) | 0.66 |
Hypercholesterolemia (%) | 75/287 (26.1) | 16 (25.4) | 12 (40.0) | 0.15 |
Diabetes Mellitus (%) | 39/287 (13.6) | 11 (17.5) | 4 (13.3) | 0.61 |
Current smoker (%) | 87/285 (30.5) | 23 (36.5) | 10 (33.3) | 0.77 |
Previous MI (%) | 12/287 (4.2) | 4 (6.3) | 0 (0.0) | 0.16 |
Previous PCI (%) | 9/287 (3.1) | 4 (6.3) | 0 (0.0) | 0.16 |
Anti-anginal medication (B/N) | 54/287 (18.8) | 8/63 (12.7) | 5/29 (17.2) | 0.56 |
Killip Class II-III (%) | 24/286 (8.4) | 4 (6.3) | 2 (6.7) | 0.95 |
Angiographic and PCI details
Variable | Immediate CR (n = 63) | Staged CR (n = 30) |
p
|
---|---|---|---|
Symptom to PCI time (min) | 180 (128–307) | 203 (152–296) | 0.95 |
Radial access (%) | 50 (80.6) | 27 (90.0) | 0.26 |
Aspirin | 62 (98.4) | 30 (100) | 0.49 |
Second antiplatelet agent (n, %) | 63 (100) | 30 (100) | 1.00 |
GPI during PPCI (n, %) | 20 (31.7) | 11/29 (37.9) | 0.56 |
Bivalirudin during PPCI (n, %) | 32 (53.3) | 17/27 (63.0) | 0.40 |
Infarct related artery: | |||
Left Anterior Descending (n, %) | 20 (31.7) | 11 (36.7) | 0.64 |
Right Coronary (n, %) | 24 (38.1) | 19 (63.3) | 0.022 |
Circumflex (n, %) | 19 (30.2) | 0 (0) | 0.001 |
Visible thrombus (n, %) | 31/62 (50.0) | 26/30 (86.7) | 0.001 |
Thrombectomy catheter (%) | 39/63 (61.9) | 26/30 (86.7) | 0.015 |
Vessels with ≥75 % stenosis (n) | 1.5 ± 0.6 | 1.6 ± 0.6 | 0.82 |
Stenosis in non-IRA lesions (%) | 73.4 | 72.9 | 0.85 |
SYNTAX score (total) | 16 (12–21.5) | 18.3 (15–26) | 0.021 |
SYNTAX score (IRA) | 8 (5.5–11) | 9.5 (8–16) | 0.043 |
SYNTAX score (NIRAs) | 6 (4–9) | 7 (4.8–12) | 0.24 |
Rentrop grade | 0 (0–1) | 1 (0–1) | 0.35 |
Rentrop grade 2–3 pre PCI (n, %) | 7/63 (11.1) | 3/30 (10.0) | 0.87 |
APPROACH area at risk (%) | 26.0 ± 11.7 | 29.2 ± 10.8 | 0.21 |
TIMI grade pre PCI | 0 (0–1) | 0 (0–0) | 0.47 |
TIMI grade post PCI | 3 (3–3), 2.92 ± 0.4 | 3 (3–3), 2.77 ± 0.5 | 0.023 |
IRA no-reflow (n, %) | 1 (1.6) | 7 (23.3) | <0.001 |
GPI at NIRA PCI (n, %) | 20 (31.7) | 4 (7.7) | 0.06 |
Bivalirudin during NIRA PCI (n, %) | 32/60 (53.3) | 3/28 (10.7) | <0.001 |
GPI or Bivalirudin at NIRA PCI (n, %) | 50/60 (87.7) | 7/28 (25.0) | <0.001 |
Total Contrast dose (ml) | 295 (213–350) | 390 (266–555) | 0.002 |
Total Screening time (min) | 15.5 (12–21) | 21 (17–43.3) | 0.001 |
Total Procedure length (IRA + NIRA, min) | 58 (38.5–72.8) | 91 (67–154.3) | <0.001 |
IRA PCI procedure length (min) | 53 (35–70.5) | 55 (37.5–81.3) | 0.08 |
Total number of stents (n) | 2.8 ± 1.1 | 3.4 ± 1.4 | 0.034 |
Number of stents in IRA (n) | 1.3 ± 0.6 | 1.6 ± 0.8 | 0.09 |
Number of stents in NIRAs (n) | 1.5 ± 0.8 | 1.8 ± 1.0 | 0.026 |
CMR data
Pre-discharge CMR
Variable | Immediate CR (n = 63) | Staged CR (n = 30) |
p
|
Peak CK (IU/L) | 939 (627–1567) | 1508 (938–2280) | 0.05 |
Pre-discharge CMR | |||
Total Infarct Size (% LVM) | 11.6 (6.8–18.2) 13.5 ± 11.4 | 19.7 (11.7–37.6) 22.6 ± 14.5 | 0.016
(0.012)*
|
Time from PPCI (days) | 2.3 (1.7–3.2) | 4.1 (2.7–5.4) | <0.001 |
Infarct on LGE (%) | 60 (95.2) | 30 (100) | 0.22 |
Patients with >1 acute infarct | 7 (11.1) | 9 (30.0) | 0.024 |
IRA Infarct size (% LVM) | 11.1 (5.4–17.4) 12.5 ± 10.0 | 19.1 (8.8–35.2) 20.9 ± 14.6 | 0.039
(0.05)*
|
Non-IRA Infarct size (% LVM) | 0.9 ± 3.2 | 1.7 ± 3.6 | 0.11
(0.65)*
|
Total acute infarcts (% LVM) | 11.6 (6.8–17.6) 13.0 ± 10.3 | 19.1 (10.2–37.1) 21.7 ± 14.8 | 0.006
(0.025)*
|
Area at risk (% LVM) | 31.4 ± 12.5 | 33.1 ± 10.8 | 0.57 |
MSI§ (%) | 61.7 (37.4–75.5) | 35.1 (5.9–66.4) | 0.008
(0.034)*
|
MVO present (n %) | 34/63 (54.0) | 21/30 (70.0) | 0.14 |
MVO (% LVM) | 0.07 (0.00–0.93) | 0.44 (0.00–6.1) | 0.032
(0.024)*
|
LVMI (g/m2) | 52.5 (47.7–61.0) | 51.5 (45.6–63.0) | 0.55 |
LVEDVI (ml/m2) | 89.9 (78.4–110.0) | 89.7 (82.8–102.9) | 0.43 |
LVEF (%) | 47.4 ± 9.4 | 42.2 ± 10.2 | 0.019 |
Follow-up CMR |
n = 53 |
n = 26 | |
LVMI (g/m2) | 45.2 (38.8–52.3) | 47.4 (40.9–51.6) | 0.71 |
LVEDVI (ml/m2) | 92.5 (80.5–105.5) | 93.9 (83.3–113.6) | 0.28 |
LVEF (%) | 50.9 ± 9.4 | 46.7 ± 8.9 | 0.06 |
Infarct on LGE (n,%) | 51 (96.2) | 26 (100) | 0.32 |
Patients with >1 infarct (%) | 9 (17.0) | 9 (34.6) | 0.08 |
IS (% LVM) | 5.7 (2.4–10.4) | 13.5 (4.6–23.3) | 0.004
(0.044)*
|